Menopause-Related Vaginal Changes May Affect Comfort and Sexual Desire

On October 16, 2026, Infobae published a report on how menopause-related changes in vaginal tissue and microbiota may contribute to discomfort without explaining sexual desire on their own. Updated October 20, it drew on comments from Ana Sierra, a psychonutritionist and head of the Psychonutrition Service at Clínica Neogenia.

Does this report change the standard of care?

The report does not announce a new standard of care. It describes an approach that includes vaginal moisturizers or lubricants and prescribed local treatments when indicated. Pelvic-floor physiotherapy and psychological or sexological support appear among the possible components of care, depending on the problem being assessed.

The narrower idea it challenges is that falling estrogen must lead from dryness straight to reduced desire. Sierra’s explanation keeps tissue-related symptoms in view without making them the explanation for every change in sexuality. For women trying to understand an uncomfortable or unfamiliar experience, that distinction matters: relief from pain and support for desire may be different clinical goals.

What can happen to vaginal tissue during menopause?

Infobae describes several possible changes associated with falling estrogen. These involve both the tissue itself and its local environment:

• Vaginal tissue may become thinner and less elastic. Sierra’s account presents this as a plausible pathway connecting hormonal change with discomfort. The explanation concerns physical changes in tissue, rather than an assumption about a woman’s interest in sex or her relationship.
• Lubrication and vaginal pH may change. The report describes reduced lubrication and a rise in vaginal pH. It also describes a reduction in Lactobacillus species, bacteria that help maintain an acidic vaginal environment. These are related parts of the account rather than separate explanations for every symptom.
• Symptoms may extend beyond dryness. The report groups vaginal dryness, stinging or irritation, urinary discomfort and pain during sex under genitourinary syndrome of menopause, often shortened to GSM. Its scope therefore includes everyday comfort and urinary symptoms, not only what happens during sexual activity.

That wider description matters editorially. A conversation limited to whether sex hurts may leave other discomfort outside the discussion. Sierra’s account instead places vaginal and urinary experiences within the same clinical picture.

How much does the microbiota explain?

The microbiota discussion is an expert explanation in a news report, not the result of a new clinical trial. Its limits belong alongside the proposed mechanisms:

• Microbiota composition does not predict symptom severity by itself. The report explicitly cautions that having more lactobacilli does not necessarily mean that symptoms will disappear. A biological feature of the vaginal environment is not the same thing as a complete account of someone’s discomfort.
• The gut connection remains a qualified explanation. Sierra discusses the estrobolome, described as intestinal microbial genes that can produce enzymes involved in estrogen metabolism. The report does not establish a single causal chain linking gut microbes with vaginal symptoms, mood and sexual desire in every woman.
• That mechanism does not establish a probiotic remedy. Sierra’s account says the evidence does not support promising that probiotics will restore lubrication or desire. It also does not support recommending them as a general answer to vaginal dryness, pain or reduced sexual interest.

The practical implication is to keep the person’s symptoms at the centre of assessment. An appealing explanation about bacteria should not become a shortcut around understanding what is actually uncomfortable or what has changed.

Why can someone want sex but still feel dry?

Sierra makes a distinction that can easily disappear in discussions of menopause: lubrication and desire are not interchangeable. Her account separates several experiences that may otherwise be grouped together:

• Desire may be present alongside pain or reduced lubrication. Less lubrication does not necessarily mean less interest in sex. Treating dryness as a measure of desire can therefore misrepresent what a woman is experiencing.
• Persistent discomfort may affect interest. The report describes how repeated pain can reduce interest in sexual activity. In that situation, the discomfort deserves attention rather than being treated only as a problem of motivation or attraction.
• Other influences may shape desire. Sierra names disrupted sleep and fatigue among the possible contributors. Her account also includes stress, mood and relationship circumstances. Hormonal changes and some medications may matter too, with experiences varying among women.

For assessment, these are different starting points. Wanting intimacy but anticipating pain is not the same experience as feeling little interest while exhausted or sleeping poorly. Refemina’s discussion of separating sexual comfort from interest develops that distinction without treating either concern as less legitimate.

The useful question is not simply whether desire has declined. It is what the change feels like and what else is happening around it.

How can pain affect later sexual experiences?

The report also describes a possible cycle in which the experience of pain influences what happens next:

• Repeated painful sex may create anticipation of further pain. Sierra describes fear of the discomfort returning as one part of the picture. This adds another dimension to assessment beyond the tissue symptoms alone.
• Anticipation may be accompanied by pelvic-floor tension. In the report’s account, that tension can complicate sexual response. This is why a muscular issue may be relevant for some women, rather than something to assume is present in everyone with dryness.
• The brain’s involvement does not make pain imaginary. Sierra explicitly rejects that interpretation. Acknowledging fear or anticipation should not become a reason to dismiss the physical experience or suggest that the woman is creating it.

This framing gives psychological support a place without using it to invalidate pain. It also connects with the broader question of rebuilding intimacy after painful experiences, where comfort and confidence both deserve attention.

What makes a clinical conversation more useful?

For symptoms that persist or affect quality of life, the report points toward clinician assessment. Sierra’s central recommendation is to understand the pattern rather than treating one complaint in isolation. A discussion can distinguish several questions:

• What is the main difficulty? Dryness or irritation may be the concern. Pain during sex or reduced interest may be more prominent. Describing which experience is most troubling gives the conversation a clearer starting point than using a broad label such as sexual problems.
• Are vaginal and urinary symptoms occurring together? The report includes both within its account of menopause-associated genitourinary symptoms. Bringing them into the same discussion reflects that wider scope without deciding the diagnosis in advance.
• What else has changed? Sierra advises attention to sleep and emotional wellbeing alongside other relevant health factors. The wider context belongs in the assessment, rather than being treated as unrelated background.

The aim is not for a woman to identify the mechanism herself. It is to bring a sufficiently clear description to qualified care. An assessment based on the symptom pattern keeps the focus on what needs explaining instead of starting with a presumed hormonal cause.

Which kinds of support does the report describe?

Sierra’s account presents several possible components of care. They address different parts of the problem rather than forming a package that every woman needs:

• Vaginal moisturizers and lubricants. The report includes these among possible supports for vaginal comfort. Their place in the discussion concerns dryness and discomfort, not a judgment about whether someone has enough desire.
• Prescribed local treatments. Locally applied hormonal options are mentioned when indicated, alongside other prescribed therapies. Choosing a prescribed treatment is a matter for the clinician assessing the symptoms and the individual’s circumstances.
• Pelvic-floor physiotherapy. The report includes this where a muscular issue is present. Its relevance follows from the assessment of that issue, not from a blanket assumption that all menopause-related discomfort has a pelvic-floor component.
• Psychological or sexological support. Sierra includes these approaches where fear of pain or the wider effects on sexual wellbeing are relevant. Their inclusion recognises that care can address emotional and relational experiences without denying tissue-related symptoms.

The distinction between these options is more useful than presenting them as competing explanations. The report allows for physical discomfort and wider sexual concerns to receive attention within the same care conversation.

For the reader, the practical takeaway is a discussion about the problem being addressed: vaginal comfort, muscular tension or the effects on intimacy. Treatment decisions belong with qualified care, while the woman’s own account remains central to defining the concern.

What should this mean for clinical practice?

The useful direction for clinical practice is more precise assessment: address tissue-related discomfort while giving desire its own physical, emotional and relational context.

How Refemina helps

Vaginal discomfort and changing desire raise overlapping questions that a hormone-only explanation may leave unresolved. Refemina helps women navigating midlife distinguish hormonal changes from concerns with several possible contributors through research-led coverage of sexual wellbeing and confidence, providing clear context without turning a complex personal experience into a single treatment opportunity.

Explore Resources

Sources

1. La menopausia altera la microbiota vaginal y puede afectar al deseo sexual